Restoring function
in Alzheimer’s, Huntington's and other diseases caused by cellular dysfunction

Platform & products

reMYND is developing first-in-class treatments to restore function in patients with Alzheimer's, Huntington's, as well as other diseases caused by cellular dysfunction, backed by a proprietary drug discovery platform:

Lead Alzheimer's program

Providing an immediate cognitive improvement by restoring synaptic function and reducing as well aBeta as Tau pathology over time.

Published in Science. Picked up by BioCentury, BioWorld, Nature Reviews Drug Discovery and local news.

Lead Huntington's program

Restoring cortico-striatal transmission and regenerating the brain.

Discovery programs

Discovery programs with in vivo proof-of-concept in Epilepsy. Proof-of-concept in ALS is ongoing.


Our Contract Research Organization (CRO) helps our clients assess the effects of their experimental Alzheimer and other neurodegenerative disease treatments in our proprietary mouse models.

We serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. We have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. We have helped our clients to be the first to demonstrate the synergistic effect of a BACE inhibitor and an aBeta antibody, the effect of Tau antibody on aBeta, the effect of donepezil on brain Abeta, …

Learn more about our services

About us

reMYND is a biotech company developing treatments for Alzheimer’s, Huntington's, epilepsy and other diseases caused by cellular dysfunction. It is backed by a proprietary drug discovery platform, which enables the identification of novel mechanisms-of-action, targets and first-in-class small molecules. reMYND’s most advanced program is ReS19-T, an investigational compound for the treatment of Alzheimer’s, currently in CTA-enabling studies.

In addition, reMYND has a dedicated Contract Research Organization (CRO), which focuses on CNS disorders. The team helps clients to assess the pharmacokinetics, pharmacodynamics and efficacy of their experimental treatments in reMYND’s proprietary animal models. The CRO has a global client base, including the US, Europe and Japan.

reMYND has been substantially supported by grants from VLAIO, the European Union and The Michael J Fox Foundation.